The most exciting part of this Texas startup funding roundup is that Houston brought in more dollars than Dallas. Getty Images

When it comes to startup funding, Texas saw only a small jump in startup investments made, according to Crunchbase. However, when you look at funds coming into Houston companies, the Bayou City's numbers soared.

Houston raked in $251 million of the state's total $817.9 million for the second quarter. Last quarter, the city posted a mere $44.7 million of investment into local startups, which was previously a huge drop from the $121.4 million reported in Q4 2018, according to Crunchbase.

The state's VC activity only increased by less than $10 million, with both Austin and Dallas taking huge hits following their strong starts in Q1. VCs invested $411.11 million into Austin startups in Q2, which is a 19 percent drop from Q1's $493.18 million, Crunchbase's Mary Ann Azevedo reports. Dallas also saw a drop of around $100 million in investments between quarters. Dallas startups only brought in $148.5 million in Q2 compared to $245.4 million in Q1.

Chart via news.crunchbase.com

Houston's biggest deal for the quarter was AlloVir's $120 million Series B, which closed in May. The biotech company founded at Baylor's Center for Cell and Gene Therapy is currently in clinical trials for its immunotherapy technology and also announced with the round closing that it joined the ElevateBio — a Boston-based organization that combines a group of cell and gene therapy companies — portfolio.

Here are some other Houston startup deals that closed in Q2. (Note: Not all of these deals are necessarily included in Crunchbase's report.)

Houston VC deals in April:

  • Innovapptive, a software-as-a-service company with clients in industrial industries, closed on a $16.3 million Series A investment. Read more.
  • OAG Analytics, which uses artificial intelligence in the oil and gas industry, has closed its second round of strategic funding. The exact amount of the raise was not disclosed by OAG, but according to a Form D filing, the company expressed that it was raising $8.72 million in this round. Read more.

Houston VC deals in May:

  • Data Gumbo Corp., a blockchain-as-a-service company, closed on a $6 million Series A round. Read more.
  • Information technology automation and management company, Liongard, closed its Series A round at $4.5 million. Read more.
  • Tachyus, the data-driven software company has closed its Series B fundraising round at $15 million. Read more.
  • Fast-growing chemicals manufacturer, Solugen Inc., the only producer of bio-based peroxide solutions, announced that its $32 million Series B funding round has closed. Read more.

Houston VC deals in June: 

  • Following a $20 million commitment from Sanford Health, regenerative medicine and cell therapy company, InGeneron Inc., has extended its Series D round to $43 million. Read more.
  • Iownit Capital and Markets Inc. announced that it closed a $4.5 Seed round of funding. Read more.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.